a combination therapy including tislelizumab

COMBINATION_PRODUCT2 trials

Sponsors

Fudan University, LI XIN-XIANG

Conditions

Advanced Rectal CancerDistal MetastasisLiver MetastasisMicrosatellite Stable Colorectal CarcinomaPulmonary Metastasis

Phase 2

A Combination Therapy Including Anti-PD-1 Immunotherapy in Rectal Cancer With Refractory Distal Metastasis

LI XIN-XIANGAdvanced Rectal Cancer, Distal Metastasis

Start: 2022-12-01End: 2024-12-01Target: 51Updated: 2022-11-15

A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis

Not yet recruitingNCT05359393

Fudan UniversityAdvanced Rectal Cancer, Liver Metastasis, Microsatellite Stable Colorectal Carcinoma +1

Start: 2022-12-01End: 2027-09-01Target: 52Updated: 2022-11-14

Related Papers

Radiotherapy followed by CAPOX plus tislelizumab in microsatellite-stable rectal cancer with synchronous resectable metastases: Updated results of the MIRACLE-1 study.

Journal of Clinical Oncology2026-05-28

Radiotherapy followed by systemic therapy and tislelizumab in microsatellite-stable rectal cancer with synchronous unresectable metastases: Updated results of the MIRACLE-2 study.

Journal of Clinical Oncology2026-05-27

Radiotherapy followed by systemic therapy and tislelizumab in MSS rectal cancer with liver metastases: Using single-cell RNA sequencing to reveal cellular dynamics in primary rectal cancer and paired liver metastases of patients enrolled in the MIRACLE-1 and MIRACLE-2 studies.

Journal of Clinical Oncology2025-05-28

Radiotherapy followed by CAPOX and tislelizumab in MSS locally advanced rectal cancer with resectable metastases: Results of the MIRACLE-1 study.

Journal of Clinical Oncology2025-05-28

MIRACLE1: Phase II study of radiotherapy followed by CapeOx and tirelizumab as first-line treatment in MSS rectal cancer with synchronous resectable liver/lung metastases.

Journal of Clinical Oncology2024-06-011 citations